A long-term follow-up study to assess bone mineral density in subjects with uterine fibroids completing the Phase 3 studies of linzagolix, PRIMROSE 1 or PRIMROSE 2
Latest Information Update: 23 Feb 2023
At a glance
- Drugs Linzagolix (Primary) ; Estradiol
- Indications Bone disorders
- Focus Therapeutic Use
- Acronyms PRIMROSE 3
- Sponsors Kissei Pharmaceutical; ObsEva
- 23 Feb 2023 This trial has been completed in Latvia (End Date: 14 Nov 2022), according to European Clinical Trials Database record.
- 02 Feb 2023 This trial has been completed in Poland, according to European Clinical Trials Database record.
- 19 Dec 2022 This trial has been completed in Hungary, according to European Clinical Trials Database record.